

1 **Adherence to a healthful plant-based diet and risk of**  
2 **mortality among individuals with chronic kidney disease: A**  
3 **prospective cohort study**

4 ***Running Title: Plant-based diets and mortality in CKD***

---

5

6 **Alysha S. Thompson<sup>1</sup>, Martina Gaggi<sup>2</sup>, Nicola P. Bondonno<sup>1,3,4</sup>, Amy Jennings<sup>1</sup>, Joshua K.**  
7 **O'Neill<sup>1</sup>, Claire Hill<sup>5</sup>, Nena Karavasiloglou<sup>6,7,8</sup>, Sabine Rohrmann<sup>6,7</sup>, Aedín Cassidy<sup>1\*</sup> and**  
8 **Tilman Kühn<sup>1,2,9\*</sup>**

9

10 <sup>1</sup>The Institute for Global Food Security, School of Biological Sciences, Queen's University Belfast,  
11 Northern Ireland, UK

12 <sup>2</sup>Medical University of Vienna, Center for Public Health, Public Health Nutrition, Vienna, Austria

13 <sup>3</sup>Danish Cancer Institute, Copenhagen, Denmark

14 <sup>4</sup>Nutrition & Health Innovation Research Institute, School of Medical and Health Sciences, Edith  
15 Cowan University, Joondalup, WA, Australia

16 <sup>5</sup>Centre for Public Health, Queen's University Belfast, Belfast, United Kingdom

17 <sup>6</sup>Division of Chronic Disease Epidemiology; Epidemiology, Biostatistics and Prevention Institute  
18 (EBPI), University of Zurich, Zurich, Switzerland

19 <sup>7</sup>Cancer Registry of the Cantons Zurich, Zug, Schaffhausen and Schwyz, Institute of Pathology and  
20 Molecular Pathology, University Hospital Zurich, Zurich, Switzerland

<sup>8</sup>European Food Safety Authority, Parma, Italy

21 <sup>9</sup>University of Vienna, Department of Nutritional Sciences, Vienna, Austria

22

23 **\*Correspondence:** [t.kuhn@qub.ac.uk](mailto:t.kuhn@qub.ac.uk) and [a.cassidy@qub.ac.uk](mailto:a.cassidy@qub.ac.uk)

24 **Corresponding Authors:** Prof Dr Tilman Kuhn and Prof Aedín Cassidy

25 Queen's University Belfast

26 Institute for Global Food Security (IGFS) / School of Biological Sciences

27 19 Chlorine Gardens

28 Belfast BT9 5DL

29 UK

30 Email: [t.kuhn@qub.ac.uk](mailto:t.kuhn@qub.ac.uk)

31 Telephone: +44 28 9097 1387

32 **Funding Source:** Alysha S. Thompson holds a PhD studentship of the Department for the Economy  
33 (DfE), Northern Ireland.

34 **Word count:** 3,583

35

36

37

38

39

40

41

42

43

44

45

46

47

48 **Abstract**

49 **Background:** Plant-rich dietary patterns may protect against negative health outcomes  
50 among individuals with chronic kidney disease (CKD), although aspects of plant-based diet  
51 quality have not been studied. This study aimed to examine associations between healthful  
52 and unhealthful plant-based dietary patterns with risk of mortality among CKD patients for  
53 the first time.

54 **Methods:** This prospective analysis included 4,807 UK Biobank participants with CKD at  
55 baseline. We examined associations of adherence to both the healthful plant-based diet  
56 index (hPDI) and unhealthful plant-based diet index (uPDI), calculated from repeated 24-  
57 hour dietary assessments, with risk of mortality using multivariable Cox proportional hazard  
58 regression models.

59 **Results:** Over a 10-year follow-up, 675 deaths were recorded. Participants with the highest  
60 hPDI scores had a 33% lower risk of mortality [HR<sub>Q4vsQ1</sub> (95% CI): 0.67 (0.53-0.84),  $p_{\text{trend}} =$   
61  $<0.001$ ], while those with the highest uPDI scores had a 49% higher risk [1.49 (1.18-1.89),  
62  $p_{\text{trend}} = 0.004$ ], compared to participants with the lowest respective scores and following  
63 adjustment for other dietary and lifestyle factors. In food group-specific analyses, higher  
64 wholegrain intakes were associated with a 29% lower mortality risk, while intakes of refined  
65 grains, and sugar-sweetened beverages were associated a 28% and 31% higher risk,  
66 respectively.

67 **Conclusions:** In CKD patients, a higher intake of healthy plant-based foods was associated  
68 with a lower risk of mortality, while a higher intake of unhealthy plant-based foods was  
69 associated with a higher risk. These results underscore the importance of plant food quality

70 and support the potential role of healthy plant food consumption in the treatment and  
71 management of CKD to mitigate unfavourable outcomes.

72 **Key words:** Plant-based diet index; chronic kidney disease; management of CKD; mortality

## 73 **1. Introduction**

74 Chronic kidney disease (CKD) poses a significant global public health challenge. The number  
75 of CKD-attributed deaths has increased by 98% from 1990 to 2016 (~0.6 million to ~1.2  
76 million deaths), with projections that CKD will rank fifth among the leading causes of death  
77 by 2040 (1-3). Further, the burden of disability-adjusted life-years (DALYs) attributed to CKD  
78 has risen from 29<sup>th</sup> in 1990 to the 18<sup>th</sup> in 2019 (4). CKD is a progressive and comorbid  
79 condition, often leading to end-stage kidney disease (ESKD), necessitating kidney  
80 replacement therapy such as dialysis or transplantation (3, 5, 6). Notably, CKD stands out as  
81 one of the few non-communicable diseases to sustain a continual increase in associated  
82 mortality over the past two decades (1). Given CKD's substantial impact on the economy (7)  
83 and on quality of life (8), there is a pressing need to explore how dietary and lifestyle  
84 modifications can preserve kidney function and improve outcomes in CKD patients.

85 A plant-based diet (PBD) including lower amounts of animal-based foods has previously  
86 been shown to be associated with better outcomes e.g., improved insulin sensitivity and  
87 lower blood pressure and survival in individuals living with CKD (9-12). Previously, a diet  
88 promoting solely plant proteins was criticised for enhancing protein-energy wasting and  
89 malnutrition, especially in patients with CKD stage 5, however, more recent studies suggest  
90 that plant-based proteins are both nutritionally adequate and beneficial for CKD patients  
91 (13). Further, vegetarian, and vegan diets are now increasingly used to facilitate better  
92 adherence to the 2020 Kidney Disease Outcomes Quality Initiative (KDOQI) nutrition

93 guideline which advises patients with earlier stages of CKD to lower dietary protein intake to  
94 mitigate further kidney damage caused by glomerular hyperfiltration (14, 15).

95 While dietary modification to treat and manage CKD has a long tradition (16-18), the  
96 relationship between PBD quality in the form of healthful and unhealthful plant-based  
97 dietary patterns with risk of mortality in patients with early-stage CKD is unknown.

98 Therefore, this study aims to investigate the relationship between plant-based diet indices  
99 (PDIs) and the risk of all-cause mortality among individuals with CKD using data from the UK

100 Biobank cohort.

101

102

103

104

105

106

107

108

109

110

111

112

113

## 114 **2. Methods**

### 115 **2.1 Study population**

116 The UK Biobank is a large cohort study of over 500,000 middle-aged adults recruited  
117 between 2006-2010 from the United Kingdom. Participants were recruited across 22 study  
118 centres in England, Scotland and Wales and provided baseline data by completing  
119 touchscreen questionnaires, verbal interviews and undergoing physical and biological  
120 assessments (19). The UK Biobank was approved by the NHS North West Multicentre  
121 Research Ethics Committee (Ref. 11/NW/0382). All study participants provided written  
122 informed consent at recruitment.

123 For this study, 502,236 participants were screened for a prior diagnosis of CKD and available  
124 data from at least one valid 24-hr dietary assessment. Participants who withdrew their  
125 consent during follow-up, had implausible energy intakes ( $>17,573\text{KJ}$  or  $< 3,347\text{KJ}$  for men  
126 and  $> 14,644\text{KJ}$  or  $< 2,092\text{KJ}$  for women (20)), had missing covariate information, or their  
127 follow-up ended before completing the final 24-hr dietary assessment were excluded from  
128 this study. Of the 31,556 UK Biobank participants with CKD, 4,807 completed at least 1  
129 dietary assessment and were included in the present analyses (**Supplementary Figure S1**).

### 130 **2.2 Dietary assessment**

131 Dietary intake was measured using the Oxford WebQ, a self-administered and internet-  
132 based 24-hr dietary assessment tool. The Oxford WebQ assessment was issued on five  
133 separate occasions: once during the recruitment phase as part of the baseline assessment at  
134 the study centre (April 2009 – September 2010), and then on four further instances via  
135 home computer outside of the recruitment period (February 2011 – June 2012). Between  
136 April 2009 and June 2012, a minimum of 1 and a maximum of 5 assessments were

137 completed. Mean (SD) duration (years) between baseline (cycle 0) and first (cycle 1) and last  
138 (cycle 4) dietary assessments were 1.6 (1.4) and 2.3 (1.4), respectively. Further details on  
139 the Oxford WebQ have been documented elsewhere (21). The reliability of the Oxford  
140 WebQ is supported by validation studies (22-24).

### 141 **2.3 Plant-based diet indices**

142 Following methods described previously (25-27), the Oxford WebQ tool was used to  
143 construct a healthful plant-based diet index (hPDI) and unhealthful plant-based diet index  
144 (uPDI); an established scoring tool used to assess the overall adherence to a PBD,  
145 considering the quality of plant food consumption. To calculate the indices, 17 food groups  
146 were used (whole grains, fruits, vegetables, nuts, legumes and vegetarian protein  
147 alternatives, tea and coffee, fruit juices, refined grains, potatoes, sugar-sweetened  
148 beverages (SSBs), sweets and desserts, animal fat, dairy, eggs, fish or seafood, meat, and  
149 miscellaneous animal-based foods). Unlike previous studies where vegetable oils were  
150 included as a 'healthy' food component, data on vegetable oils was not available for this  
151 study. For the hPDI, healthy plant-food groups were scored positively, and unhealthy plant-  
152 food groups and animal-derived food groups were scored in the reverse. For the uPDI,  
153 positive scores were assigned to unhealthy plant-food groups and reverse scores were given  
154 to healthy plant-food groups and animal-derived food groups. For each food group, intakes  
155 of more than zero servings were ranked into sex-specific quartiles. For positive scores,  
156 participants were assigned a score between 2 and 5 (2 for the lowest quartile of intake and  
157 5 for the highest). Participants who reported zero intakes were assigned a score of 1. The  
158 pattern of scoring was inverted for reverse scores. The scores assigned to each of the 17  
159 food groups were summed to obtain the final hPDI and uPDI.

## 160 **2.4 Ascertainment of chronic kidney disease**

161 CKD cases were considered prevalent if diagnosed before the first dietary assessment via  
162 self-reported or hospital inpatient data. CKD cases were defined using the International  
163 Classification of Diseases, 10<sup>th</sup> Revision (ICD-10) codes (ICD-10 codes: N03, N06, N08, N11,  
164 N12, N13, N14, N15, N16, N18, N19, Z49, I12, I13) or Office of Population Censuses and  
165 Surveys Classification of Interventions and Procedures-version 4 (OPCS-4) codes in Hospital  
166 Inpatient data (OPCS-4 codes: L74.1-L74.6, L74.8, L74.9, M01.2, M01.3-M01.5, M01.8,  
167 M01.9, M02.3, M08.4, M17.2, M17.4, M17.8, M17.9, X40.1-X40.9, X41.1, X41.2, X41.8,  
168 X41.9, X42.1, X42.8, X42.9, and X43.1). Further information regarding the codes used to  
169 define CKD can be found in **Supplement Table S1**. Using serum creatinine, the CKD-EPI  
170 (Chronic Kidney Disease Epidemiology Collaboration) creatinine equation (28) was used to  
171 calculate glomerular filtration rate. Participants with a baseline estimated glomerular  
172 filtration rate (eGFR) <60ml/min/1.73m<sup>2</sup> were considered as having CKD.

## 173 **2.5 Ascertainment of mortality**

174 The primary outcome of this study was all-cause mortality. Death data was obtained from  
175 death certificates provided by the National Health Service England (England and Wales) and  
176 National Health Service Central Register, National Records of Scotland (Scotland). Mortality  
177 data was available until 30<sup>th</sup> November 2022 for England, Scotland, and Wales. Follow-up  
178 time was calculated from the date of the last dietary assessment and was censored at date  
179 of death, lost to follow-up, or death registry censoring date, whichever was the earliest.

## 180 **2.6 Assessment of covariates**

181 Between 2006 and 2010, participants provided information on sociodemographic, dietary,  
182 lifestyle and medical history at the assessment centre, where several types of assessments



183 were performed. A touchscreen questionnaire was used to collect information on self-  
184 reported age, sex, ethnicity, smoking status, education level and physical activity at  
185 baseline. Multimorbidity was identified through data on past and current medical conditions  
186 obtained through verbal interview at the initial assessment. Polypharmacy was also  
187 obtained through verbal interview at baseline and was defined by the number of self-  
188 reported treatments/medications taken. Prevalent diabetes was defined through self-  
189 reporting at the touchscreen questionnaire and verbal interview. Townsend deprivation  
190 index was calculated at baseline using postcodes of residence. Physical measures including  
191 waist circumference, height, and weight were manually obtained at the initial assessment  
192 by trained professionals. Height and weight were used to calculate body mass index (BMI),  
193 dividing weight (kg) by the square of height (m). Number of completed dietary assessments,  
194 energy, alcohol, and protein intake was based on the 24-hr Oxford WebQ dietary  
195 questionnaire. To calculate eGFR, the CKD-EPI (Chronic Kidney Disease Epidemiology  
196 Collaboration) creatinine equation (28) was employed using serum creatinine which was  
197 measured by enzymatic analysis on a Beckman Coulter AU5800.

## 198 **2.7 Assessment of genetic risk score of eGFR**

199 A detailed description of the genotyping, imputation, and quality control of the UK Biobank  
200 genetic data has been published previously (29). A recent GWAS by Wuttke et al. 2019 was  
201 used to identify single nucleotide polymorphisms (SNPs) associated with CKD. Using a  
202 weighted method, a polygenic risk score (PRS) of eGFR was calculated using 161 SNPs  
203 (**Supplementary Table S2**). A higher PRS of eGFR indicates a lower genetic risk of kidney  
204 diseases. Additional information on the quality control procedures implemented in this  
205 study have been described in the **Supplementary Methods**.

## 206 **2.8 Statistical analysis**

207 Baseline characteristics of the study population are presented across quartiles of hPDI and  
208 uPDI scores. Continuous variables are presented as mean  $\pm$  standard deviation (SD) and  
209 categorical variables are presented as a number and percentage proportion. Associations  
210 between PDIs and total mortality were examined using Cox proportional hazards regression  
211 models, with age (years) as the timescale. Results are reported as hazard ratios (HRs) and  
212 95% confidence intervals (95% CI). Linear trend tests involved modelling the PDIs as  
213 continuous exposure variables ( $P_{\text{trend}}$ ). The proportional hazards assumption was tested by  
214 the Schoenfeld residual method. Analyses were adjusted for confounding factors using two  
215 models. Model 1 was adjusted for sex (female, male) and education (Low: CSEs or  
216 equivalent, O levels/GCSEs or equivalent; Medium: A levels/AS levels or equivalent, NVQ or  
217 HND or HNC or equivalent; High: College or University degree, other professional  
218 qualifications eg: nursing, teaching; unknown/missing/prefer not to say (15.6%)), stratified  
219 by age (5-year categories) and geographical region of recruitment (ten UK regions). Model 2  
220 was additionally adjusted for BMI (18.5-24.9 kg/m<sup>2</sup>, 25.0-29.9 kg/m<sup>2</sup>,  $\geq$ 30 kg/m<sup>2</sup>, or  
221 unknown/missing (0.4%)), waist circumference (continuous scale, cm), ethnicity (Asian,  
222 Black, Multiple, White, other/unknown/missing (1.3%)), physical activity (Metabolic  
223 Equivalent Tasks (METs) hr/week in quintiles, or unknown/missing (2.7%)), smoking status  
224 (never, previous, current, or unknown/missing (0.3%)), alcohol intake (continuous scale,  
225 g/day), energy intake (continuous scale, kJ/day), multimorbidity index (number of pre-  
226 existing long-term conditions at baseline; 0, 1, 2, or >3), polypharmacy index (total number  
227 of self-reported medications take at baseline; 0, 1-3, 4-6, 7-9, >10), Townsend deprivation  
228 index (quintiles from low to high deprivation), prevalent diabetes (no, yes), protein intake  
229 (continuous, g/day) and number of completed dietary assessments (continuous scale,

230 ranging between 1-5). In addition to main analyses, multivariable Cox regression analyses  
231 were performed for each of the 17 PDI food groups.

232 To investigate whether associations between the continuous hPDI and uPDI (10-point  
233 increments) and risk of mortality differed by population groups, analyses were stratified by  
234 age (<63 or ≥63 years), sex (male or female), smoking status (never or ever), alcohol intake  
235 (tertiles from low to high alcohol intake: low [ $<1\text{g/day}$ ], moderate [ $1\text{-}\leq 14\text{g/day}$ ] or high  
236 [ $\geq 15\text{g/day}$ ]), protein intake (<median [ $<77\text{g/day}$ ] or ≥ median [ $\geq 77\text{g/day}$ ]), eGFR (<35  
237 mL/min/1.73 m<sup>2</sup> or ≥35 mL/min/1.73 m<sup>2</sup>), PRS (tertiles from low to high PRS for eGFR) and  
238 CKD stage (stage 1-2, stage 3a-3b, or stage 4-5), testing for interactions using likelihood ratio  
239 tests (LRT). To assess the robustness of our findings, three further sets of analyses were  
240 conducted. Firstly, primary analyses were further adjusted for eGFR to account for level of  
241 kidney function. Secondly, primary analyses were further adjusted for genetic susceptibility  
242 to kidney diseases (PRS of eGFR). Thirdly, analyses were restricted to participants who had  
243 completed ≥2 dietary assessments. Finally, to assess potential reverse causation bias,  
244 sensitivity analyses were carried out excluding the first 2 years of follow-up.

245 Intraclass correlation coefficients (ICCs) were used to test the reliability of the PDIs over  
246 time. PDI scores were calculated from mean food intakes at each Oxford WebQ dietary  
247 assessment (cycle 0: April 2009 to September 2010 vs cycle 1: February 2011 to April 2011  
248 vs cycle 2: June 2011 to September 2011 vs cycle 3: October 2011 to December 2011 vs  
249 cycle 4: April 2012 to June 2012).

250 Statistical analyses were performed using Stata statistical software version 18.0 (StataCorp  
251 LLC). Two-sided *P* values were considered statistically significant.

## 252 **3. Results**

### 253 **3.1 Study participants and baseline characteristics**

254 Baseline characteristics and nutrient intakes of 4,807 study participants with CKD are shown  
255 across quartiles of hPDI and uPDI in **Table 1 and Supplementary Table S3-Table S5**. A  
256 comparison of baseline characteristics of CKD patients with and without dietary data is  
257 shown in **Supplementary Table S6**. The mean (SD) age was 60.9 (6.9), 2,452 (51.0%) were  
258 female, 543 (11.3%) had prevalent diabetes, and the mean baseline eGFR was 59.5  
259 mL/min/1.73m<sup>2</sup>. Individuals with higher scores of hPDI were more likely to be women, have  
260 a lower BMI, be more physically active and have a higher education level than those with  
261 lower scores. Individuals with higher scores of uPDI were more likely to be men, have a  
262 higher BMI, be less physically active and have a lower education level than those with lower  
263 scores.

264 The ICCs (range) for reproducibility of the PDIs over time ranged from 0.48 (39-75) to 0.53  
265 (45-79) for hPDI and 0.42 (42-72) to 0.48 (40-73) for uPDI, respectively (**Supplementary**  
266 **Table S7**).

### 267 **3.2 Plant-based diets and mortality risk**

268 During a mean (IQR) follow-up of 10.4 (0.9) years, 675 participants died. In multivariable-  
269 adjusted Cox regression models (Model 2), dose-response associations were shown for both  
270 hPDI and uPDI with risk of mortality. Participants in the highest hPDI quartile (Quartile 4  
271 (Q4)) had a 33% lower risk of mortality [HR<sub>Q4vsQ1</sub> (95% CI): 0.67 (0.53-0.84);  $p_{\text{trend}} = 0.001$ ]  
272 compared to those in the lowest hPDI quartile (Quartile 1 (Q1)) (**Table 2**). In contrast,  
273 participants in the highest uPDI quartile (Q4) had 49% higher risk of mortality [1.49 (1.18-  
274 1.89);  $p_{\text{trend}} = 0.004$ ] compared to those in the lowest uPDI quartile (Q1).

275 Of the individual PDI components, higher intakes (Q4) of wholegrains (>2.9 servings/day)  
276 was associated with a 29% lower risk of mortality [HR<sub>Q4vsQ1</sub> (95% CI): 0.71 (0.56-0.90),  $p_{\text{trend}}$   
277 = 0.02] compared to lower intakes (Q1) (zero servings/day), while higher intakes (Q4) of  
278 refined grains (2.0 servings/day) and SSBs (1.1 serving/day) was associated with a 28% and  
279 31% higher risk of mortality [1.28 (1.04-1.59),  $p_{\text{trend}}$  = 0.002; 1.31 (1.06-1.62),  $p_{\text{trend}}$  = 0.001],  
280 respectively, compared to lower intakes (Q1) (zero servings/day) (**Table 3**).

### 281 **3.3 Subgroup and sensitivity analyses**

282 For associations between hPDI and mortality, subgroup analysis showed no evidence of  
283 heterogeneity across key covariates (age, sex, smoking status, alcohol intake, protein intake,  
284 eGFR, PRS (eGFR), and CKD stage) (**Supplementary Table S8-S9**). Results remained robust in  
285 sensitivity analyses: further adjusting for eGFR, genetic susceptibility of kidney diseases and  
286 excluding participants with short follow-up duration (<2 years) (**Supplementary Tables S10-**  
287 **S12**). Stronger associations were shown between hPDI and uPDI and mortality risk in repeat  
288 analyses restricting to  $\geq 2$  dietary assessments, although  $P_{\text{trend}}$  for uPDI turned non-  
289 significant ( $p_{\text{trend}}$  = 0.08) (**Supplementary Table S13**).

290

291

292

293

294

## 295 **4. Discussion**

296 In this large-scale cohort study, higher adherence to hPDI was associated with a 33% lower  
297 risk of all-cause mortality among individuals with CKD, while a higher uPDI was associated  
298 with a 49% higher risk following full adjustment for a range of diet and lifestyle factors.  
299 Associations between PDIs and mortality were only shown for CKD patients in early stages  
300 (stages 1-2).

301 Our findings support the role of adopting a healthy plant-based dietary pattern for  
302 lengthening survival of CKD. While it's widely recognised that increased adherence to a PBD  
303 may lower mortality risk in the general population (31-33), to our knowledge, only one  
304 study currently exists on PBDs and risk of CKD progression and all-cause mortality in CKD  
305 patients from the Chronic Renal Insufficiency Cohort (CRIC) Study (34). While it's reassuring  
306 to find that our results align with those from the CRIC study, one key difference to note is  
307 that our study consisted mostly of individuals with early stage CKD (97% with CKD stages 1-  
308 3b; mean (SD) eGFR of 59.5 (18.0)), while the CIRC study was predominantly made up of  
309 CKD patients with stages 3 and 4 (70% and 18% respectively; mean (SD) eGFR of 43.4 (13.5))  
310 (35)). Collectively, these findings suggest that a healthful PBD exerts benefits across all  
311 stages of CKD, in line with previous studies to suggest that higher dietary intake of healthful  
312 plant foods lowers CKD risk through improved kidney function (36-38).

313 Several plausible biological mechanisms may explain the beneficial role of plant-rich diets on  
314 kidney health. Firstly, plant-rich diets are typically nutrient dense, providing a rich source of  
315 vitamins, minerals, and phytochemicals. Flavonoids, a group of secondary plant metabolites  
316 have shown to have renoprotective effects in CKD through their anti-inflammatory and  
317 antioxidant properties (39, 40). Supporting this, a randomized, double-blinded, placebo-

318 controlled trial previously reported dietary cocoa flavanols to improve vascular function in  
319 patients with ESKD (41). Our study also revealed that individuals with a higher hPDI  
320 consumed 39% more dietary fibre than those with a low hPDI. A recent meta-analysis of 10  
321 cohort studies indicated the potential protective effects of increasing dietary fibre  
322 consumption against all-cause mortality, cardiovascular mortality and cardiovascular disease  
323 in CKD patients (42). Moreover, previous research has demonstrated that increased dietary  
324 fibre intake is likely to reduce levels of inflammation in CKD patients (43-45). Results from  
325 an intervention trial demonstrated significantly lower levels of C-reactive protein,  
326 interleukin-6, interleukin-8, and tumour necrosis factor- $\alpha$  in haemodialysis patients  
327 supplemented with 10g and 20g of dietary fibre per day over 6 weeks (46). Further, through  
328 increased intestinal motility, dietary fibre has also been shown to play a favourable role in  
329 the gut microbiome, promoting the growth of beneficial microbiota, and decreasing uremic  
330 toxin production (47, 48). Supporting this, a meta-analysis of 14 controlled feeding trials  
331 revealed that greater dietary fibre intake was associated with lower serum urea and  
332 creatinine levels in individuals with CKD (49).

333 PBDs typically confer lower intakes of animal-based foods. Though the exact mechanisms  
334 through which animal foods such as red meat may contribute to renal toxicity are unclear,  
335 one proposed explanation is that increased consumption of animal foods leads to a high  
336 acid load in the diet (50). Higher acid load in the diet has been linked to renal toxicity and  
337 kidney function decline through metabolic acidosis in patients with CKD (51). It is also  
338 inferred that animal foods increase inflammation and promote unfavourable changes to the  
339 gut microbiome which lead to increased production of uremic toxins (52-54), potentially  
340 influencing the progression of renal disease. Although in this study, no significant  
341 associations were shown for higher meat intake and reduced mortality, evidence from the

342 Nurses' Health Study suggests that consuming two or more servings of red meat per week  
343 increases the risk of microalbuminuria (55), while the Singapore Chinese Health Study found  
344 a dose-dependent relationship between red meat intake and ESKD (56). In addition, a  
345 randomized crossover trial of postmenopausal women demonstrated that replacing meat  
346 with soy improved insulin sensitivity, offering a potential approach for managing and  
347 preventing metabolic syndrome (57)—a pathological state associated with decreased renal  
348 function (58, 59).

349 Our study also showed that higher intakes of SSBs were associated with increased mortality  
350 risk. While our findings align with those of a recent dose-response meta-analysis where  
351 greater consumption of SSBs was associated with a higher risk of all-cause mortality (60),  
352 numerous other studies have also observed that a higher intake of sugar or artificially  
353 sweetened beverages was associated with kidney function decline (61-63). Some possible  
354 biological mechanisms that may explain these associations include that SSBs contain high  
355 amounts of added sugar and lead to low satiety, contributing to weight gain and obesity (64,  
356 65). Moreover, SSBs often contain high levels of fructose which has previously been linked  
357 to renal disease and its progression through hyperuricemia (66, 67) and kidney stone  
358 formation (68).

#### 359 **4.1 Limitations**

360 There are some limitations of this study. Firstly, despite our efforts to account for various  
361 potential confounding factors, unmeasured or residual confounding could still be present  
362 given the observational design of the study, so results should be interpreted with caution.  
363 Secondly, the PDI was based on self-reported 24-hr dietary data, introducing the possibility  
364 of measurement error and recall bias. Thirdly, this study was confined to individuals with



365 pre-existing CKD; to maximise the sample size, participants with data from at least one 24-h  
366 dietary assessment were included (2,118 (44.1%) of 4,807 completed one dietary  
367 assessment). While a single dietary assessment limits the reproducibility of food group level  
368 intakes, this study, in addition to others, has shown that diet quality scores including the  
369 PDIs are reproducible over time based on single dietary recalls (21, 69, 70). Fourthly,  
370 primary care data was not used to identify CKD cases, potentially constraining the sample  
371 size of this study. Despite this, eGFR was also used to classify patients with CKD, which is  
372 considered an optimal marker of kidney function (71). Finally, subgroup analyses by  
373 ethnicity were not conducted due to the limited number of non-white participants in the  
374 study (344 (7.2%) of 4,807), further highlighting that the UK Biobank is not representative of  
375 the UK population, limiting the generalisability of our findings (72).

376

## 377 **5. Conclusion**

378 In conclusion, better adherence to a healthy PBD was associated with a lower risk of all-  
379 cause mortality independent of a wide range of factors, including eGFR and genetic  
380 susceptibility to kidney diseases, while higher adherence to an unhealthy PBD was  
381 associated with a higher risk. While existing recommendations for nutritional management  
382 of CKD primarily target individual dietary components i.e., protein and sodium (71, 73), our  
383 data support the shift towards healthy plant-based dietary patterns, specifically through  
384 increasing intakes of wholegrains and lowering intakes of refined grains and sugar-  
385 sweetened beverages, to better manage and treat CKD patients. Our findings underscore  
386 the importance of conducting large-scale clinical trials to further explore the impact of  
387 plant-based dietary patterns on clinical outcomes among individuals with CKD.

388

389 **Funding statement:** This research was conducted using UK Biobank funded and sourced  
390 data (application 64426). The UK Biobank was established by the Wellcome Trust, the  
391 Medical Research Council, the UK Department of Health, and the Scottish Government. The  
392 UK Biobank has also received funding from the Welsh Assembly Government, the British  
393 Heart Foundation, and Diabetes United Kingdom, Northwest Regional Development Agency,  
394 Scottish Government. In addition, Alysha S. Thompson holds a PhD studentship of the  
395 Department for the Economy (DfE), Northern Ireland. This work was in part supported by  
396 the Co-Centre for Sustainable and Resilient Food Systems.

397 **Conflict of interest:** None were reported.

398 **Authors' contributions:** Design and concept: AT, TK, AC; database development: AT, ATR,  
399 JKO, CH; analysed and interpreted data: AT, AC, TK; drafted manuscript: AT, TK, AC; provided  
400 critical review of the manuscript: all authors; guarantors of the work: AT and TK.

401 **Data sharing statement:** UK Biobank data can be requested by all bona fide researchers for  
402 approved projects, including replication, through <https://www.ukbiobank.ac.uk/>. This  
403 research was conducted using UK Biobank funded and sourced data (application 64426).

404 **Ethics statement:** All UK Biobank participants provided informed consent to participate and  
405 be followed through linkage to their health records. The UK Biobank study received ethical  
406 approval from the NHS North West Multicentre Research Ethics Committee (Ref.  
407 11/NW/0382).

408 Disclaimer: "The views expressed in this publication are those of the authors and should not  
409 be interpreted as representing the official position of the European Food Safety Authority  
410 (EFSA). Therefore, the present article is published under the sole responsibility of the

411 authors, and may not be considered as an EFSA scientific output. EFSA cannot be held  
412 accountable for any errors or inaccuracies that may appear."

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

## 431 **References**

- 432 1. Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al.  
433 Global, regional, and national burden of chronic kidney disease, 1990–2017: a  
434 systematic analysis for the Global Burden of Disease Study 2017. *The lancet*.  
435 2020;395(10225):709-33.
- 436 2. Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey  
437 M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-  
438 specific mortality for 250 causes of death: reference and alternative scenarios  
439 for 2016-40 for 195 countries and territories. *Lancet*. 2018;392(10159):2052-  
440 90.
- 441 3. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, et al. Analysis of the  
442 Global Burden of Disease study highlights the global, regional, and national  
443 trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney*  
444 *International*. 2018;94(3):567-81.
- 445 4. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al.  
446 Global burden of 369 diseases and injuries in 204 countries and territories,  
447 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  
448 *The lancet*. 2020;396(10258):1204-22.
- 449 5. Levey AS, Coresh J. Chronic kidney disease. *The lancet*.  
450 2012;379(9811):165-80.
- 451 6. Levin A, Tonelli M, Bonventre J, Coresh J, Donner J-A, Fogo AB, et al.  
452 Global kidney health 2017 and beyond: a roadmap for closing gaps in care,  
453 research, and policy. *The Lancet*. 2017;390(10105):1888-917.
- 454 7. Jha V, Al-Ghamdi SM, Li G, Wu M-S, Stafylas P, Retat L, et al. Global  
455 Economic Burden Associated with chronic kidney disease: a pragmatic review  
456 of medical costs for the Inside CKD Research Programme. *Advances in Therapy*.  
457 2023;40(10):4405-20.
- 458 8. Kefale B, Alebachew M, Tadesse Y, Engidawork E. Quality of life and its  
459 predictors among patients with chronic kidney disease: A hospital-based cross  
460 sectional study. *PLOS ONE*. 2019;14(2):e0212184.
- 461 9. Kelly JT, Palmer SC, Wai SN, Ruospo M, Carrero J-J, Campbell KL, et al.  
462 Healthy dietary patterns and risk of mortality and ESRD in CKD: a meta-analysis  
463 of cohort studies. *Clinical journal of the American Society of Nephrology*:  
464 *CJASN*. 2017;12(2):272.

- 465 10. González-Ortiz A, Xu H, Avesani CM, Lindholm B, Cederholm T, Risérus U,  
466 et al. Plant-based diets, insulin sensitivity and inflammation in elderly men with  
467 chronic kidney disease. *Journal of Nephrology*. 2020;33(5):1091-101.
- 468 11. Yuzbashian E, Asghari G, Mirmiran P, Amouzegar-Bahambari P, Azizi F.  
469 Adherence to low-sodium Dietary Approaches to Stop Hypertension-style diet  
470 may decrease the risk of incident chronic kidney disease among high-risk  
471 patients: a secondary prevention in prospective cohort study. *Nephrology  
472 Dialysis Transplantation*. 2018;33(7):1159-68.
- 473 12. Tyson CC, Davenport CA, Lin P-H, Scialla JJ, Hall R, Diamantidis CJ, et al.  
474 DASH diet and blood pressure among black Americans with and without CKD:  
475 the Jackson Heart Study. *American Journal of Hypertension*. 2019;32(10):975-  
476 82.
- 477 13. Joshi S, Shah S, Kalantar-Zadeh K. Adequacy of plant-based proteins in  
478 chronic kidney disease. *Journal of Renal Nutrition*. 2019;29(2):112-7.
- 479 14. Ikizler TA, Burrowes JD, Byham-Gray LD, Campbell KL, Carrero J-J, Chan  
480 W, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update.  
481 *American Journal of Kidney Diseases*. 2020;76(3, Supplement 1):S1-S107.
- 482 15. Kistler BM, Moore LW, Benner D, Biruete A, Boaz M, Brunori G, et al. The  
483 International Society of Renal Nutrition and Metabolism Commentary on the  
484 National Kidney Foundation and Academy of Nutrition and Dietetics KDOQI  
485 Clinical Practice Guideline for Nutrition in Chronic Kidney Disease. *J Ren Nutr*.  
486 2021;31(2):116-20.e1.
- 487 16. Anderson CAM, Nguyen HA, Rifkin DE. Nutrition Interventions in Chronic  
488 Kidney Disease. *Medical Clinics of North America*. 2016;100(6):1265-83.
- 489 17. Yan B, Su X, Xu B, Qiao X, Wang L. Effect of diet protein restriction on  
490 progression of chronic kidney disease: A systematic review and meta-analysis.  
491 *PLoS One*. 2018;13(11):e0206134.
- 492 18. Ko GJ, Rhee CM, Kalantar-Zadeh K, Joshi S. The Effects of High-Protein  
493 Diets on Kidney Health and Longevity. *J Am Soc Nephrol*. 2020;31(8):1667-79.
- 494 19. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK  
495 biobank: an open access resource for identifying the causes of a wide range of  
496 complex diseases of middle and old age. *PLoS medicine*. 2015;12(3):e1001779-  
497 e.
- 498 20. Schofield WN, Schofield C, James WPT. Basal metabolic rate: review and  
499 prediction, together with an annotated bibliography of source material. 1985.

- 500 21. Perez-Cornago A, Pollard Z, Young H, van Uden M, Andrews C, Piernas C,  
501 et al. Description of the updated nutrition calculation of the Oxford WebQ  
502 questionnaire and comparison with the previous version among 207,144  
503 participants in UK Biobank. *European Journal of Nutrition*. 2021;60(7):4019-30.
- 504 22. Greenwood DC, Hardie LJ, Frost GS, Alwan NA, Bradbury KE, Carter M, et  
505 al. Validation of the Oxford WebQ Online 24-Hour Dietary Questionnaire Using  
506 Biomarkers. *Am J Epidemiol*. 2019;188(10):1858-67.
- 507 23. Galante J, Adamska L, Young A, Young H, Littlejohns TJ, Gallacher J, et al.  
508 The acceptability of repeat Internet-based hybrid diet assessment of previous  
509 24-h dietary intake: administration of the Oxford WebQ in UK Biobank. *British*  
510 *Journal of Nutrition*. 2016;115(4):681-6.
- 511 24. Liu B, Young H, Crowe FL, Benson VS, Spencer EA, Key TJ, et al.  
512 Development and evaluation of the Oxford WebQ, a low-cost, web-based  
513 method for assessment of previous 24 h dietary intakes in large-scale  
514 prospective studies. *Public Health Nutr*. 2011;14(11):1998-2005.
- 515 25. Satija A, Bhupathiraju SN, Rimm EB, Spiegelman D, Chiuve SE, Borgi L, et  
516 al. Plant-Based Dietary Patterns and Incidence of Type 2 Diabetes in US Men  
517 and Women: Results from Three Prospective Cohort Studies. *PLOS Medicine*.  
518 2016;13(6):e1002039.
- 519 26. Satija A, Bhupathiraju SN, Spiegelman D, Chiuve SE, Manson JE, Willett  
520 W, et al. Healthful and Unhealthful Plant-Based Diets and the Risk of Coronary  
521 Heart Disease in U.S. Adults. *Journal of the American College of Cardiology*.  
522 2017;70(4):411-22.
- 523 27. Heianza Y, Zhou T, Sun D, Hu FB, Qi L. Healthful plant-based dietary  
524 patterns, genetic risk of obesity, and cardiovascular risk in the UK biobank  
525 study. *Clinical Nutrition*. 2021;40(7):4694-701.
- 526 28. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro III AF, Feldman HI, et  
527 al. A new equation to estimate glomerular filtration rate. *Annals of internal*  
528 *medicine*. 2009;150(9):604-12.
- 529 29. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The  
530 UK Biobank resource with deep phenotyping and genomic data. *Nature*.  
531 2018;562(7726):203-9.
- 532 30. Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of  
533 genetic loci associated with kidney function from analyses of a million  
534 individuals. *Nature genetics*. 2019;51(6):957-72.
- 535 31. Jafari S, Hezaveh E, Jalilpiran Y, Jayedi A, Wong A, Safaiyan A, et al. Plant-  
536 based diets and risk of disease mortality: a systematic review and meta-

- 537 analysis of cohort studies. *Critical Reviews in Food Science and Nutrition*.  
538 2022;62(28):7760-72.
- 539 32. Li H, Zeng X, Wang Y, Zhang Z, Zhu Y, Li X, et al. A prospective study of  
540 healthful and unhealthful plant-based diet and risk of overall and cause-  
541 specific mortality. *European Journal of Nutrition*. 2022;61(1):387-98.
- 542 33. Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al.  
543 Healthy eating patterns and risk of total and cause-specific mortality. *JAMA*  
544 *internal medicine*. 2023;183(2):142-53.
- 545 34. Amir S, Kim H, Hu EA, Ricardo AC, Mills KT, He J, et al. Adherence to  
546 Plant-Based Diets and Risk of CKD Progression and All-Cause Mortality:  
547 Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study. *American*  
548 *Journal of Kidney Diseases*. 2023.
- 549 35. Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al. Chronic Renal  
550 Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with  
551 kidney function. *Clinical Journal of the American Society of Nephrology*.  
552 2009;4(8):1302-11.
- 553 36. Kim H, Caulfield LE, Garcia-Larsen V, Steffen LM, Grams ME, Coresh J, et  
554 al. Plant-Based Diets and Incident CKD and Kidney Function. *Clin J Am Soc*  
555 *Nephrol*. 2019;14(5):682-91.
- 556 37. Haring B, Selvin E, Liang M, Coresh J, Grams ME, Petruski-Ivleva N, et al.  
557 Dietary protein sources and risk for incident chronic kidney disease: results  
558 from the Atherosclerosis Risk in Communities (ARIC) Study. *Journal of Renal*  
559 *Nutrition*. 2017;27(4):233-42.
- 560 38. Oosterwijk MM, Soedamah-Muthu SS, Geleijnse JM, Bakker SJ, Navis G,  
561 Binnenmars SH, et al. High dietary intake of vegetable protein is associated  
562 with lower prevalence of renal function impairment: results of the Dutch  
563 DIALECT-1 cohort. *Kidney international reports*. 2019;4(5):710-9.
- 564 39. de Almeida Alvarenga L, Borges NA, Moreira LdSG, Teixeira KTR, Carraro-  
565 Eduardo JC, Dai L, et al. Cranberries—potential benefits in patients with chronic  
566 kidney disease. *Food & function*. 2019;10(6):3103-12.
- 567 40. Vargas F, Romecín P, García-Guillén AI, Wangesteen R, Vargas-Tendero  
568 P, Atucha NM, et al. Flavonoids in kidney health and disease. *Frontiers in*  
569 *physiology*. 2018;9:350109.
- 570 41. Rassaf T, Rammos C, Hendgen-Cotta UB, Heiss C, Kleophas W, Dellanna  
571 F, et al. Vasculoprotective effects of dietary cocoa flavanols in patients on  
572 hemodialysis: a double-blind, randomized, placebo-controlled trial. *Clinical*  
573 *Journal of the American Society of Nephrology*. 2016;11(1):108-18.

- 574 42. Gai W, Lin L, Wang Y, Bian J, Tao Y. Relationship between dietary fiber  
575 and all-cause mortality, cardiovascular mortality, and cardiovascular disease in  
576 patients with chronic kidney disease: a systematic review and meta-analysis.  
577 *Journal of Nephrology*. 2024.
- 578 43. Xu H, Huang X, Riserus U, Krishnamurthy VM, Cederholm T, Ärnlöv J, et  
579 al. Dietary fiber, kidney function, inflammation, and mortality risk. *Clinical*  
580 *journal of the American Society of Nephrology: CJASN*. 2014;9(12):2104.
- 581 44. Krishnamurthy VMR, Wei G, Baird BC, Murtaugh M, Chonchol MB,  
582 Raphael KL, et al. High dietary fiber intake is associated with decreased  
583 inflammation and all-cause mortality in patients with chronic kidney disease.  
584 *Kidney international*. 2012;81(3):300-6.
- 585 45. Veronese N, Solmi M, Caruso MG, Giannelli G, Osella AR, Evangelou E, et  
586 al. Dietary fiber and health outcomes: an umbrella review of systematic  
587 reviews and meta-analyses. *Am J Clin Nutr*. 2018;107(3):436-44.
- 588 46. Xie L-M, Ge Y-Y, Huang X, Zhang Y-Q, Li J-X. Effects of fermentable  
589 dietary fiber supplementation on oxidative and inflammatory status in  
590 hemodialysis patients. *International journal of clinical and experimental*  
591 *medicine*. 2015;8(1):1363.
- 592 47. Mafra D, Borges N, Alvarenga L, Esgalhado M, Cardozo L, Lindholm B, et  
593 al. Dietary components that may influence the disturbed gut microbiota in  
594 chronic kidney disease. *Nutrients*. 2019;11(3):496.
- 595 48. Camerotto C, Cupisti A, D'Alessandro C, Muzio F, Gallieni M. Dietary fiber  
596 and gut microbiota in renal diets. *Nutrients*. 2019;11(9):2149.
- 597 49. Chiavaroli L, Mirrahimi A, Sievenpiper JL, Jenkins DJA, Darling PB. Dietary  
598 fiber effects in chronic kidney disease: a systematic review and meta-analysis  
599 of controlled feeding trials. *European Journal of Clinical Nutrition*.  
600 2015;69(7):761-8.
- 601 50. Remer T, editor *Acid-Base In Renal Failure: influence of diet on acid-base*  
602 *balance*. *Seminars in dialysis*; 2000: Wiley Online Library.
- 603 51. Banerjee T, Crews DC, Wesson DE, Tilea AM, Saran R, Ríos-Burrows N, et  
604 al. High dietary acid load predicts ESRD among adults with CKD. *Journal of the*  
605 *American Society of Nephrology*. 2015;26(7):1693-700.
- 606 52. Moraes C, Fouque D, Amaral ACF, Mafra D. Trimethylamine N-oxide  
607 from gut microbiota in chronic kidney disease patients: focus on diet. *Journal*  
608 *of Renal Nutrition*. 2015;25(6):459-65.



- 609 53. Ley SH, Sun Q, Willett WC, Eliassen AH, Wu K, Pan A, et al. Associations  
610 between red meat intake and biomarkers of inflammation and glucose  
611 metabolism in women. *The American journal of clinical nutrition*.  
612 2014;99(2):352-60.
- 613 54. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G. The uremic  
614 toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. *J Am Soc*  
615 *Nephrol*. 2014;25(9):1897-907.
- 616 55. Lin J, Hu FB, Curhan GC. Associations of diet with albuminuria and kidney  
617 function decline. *Clin J Am Soc Nephrol*. 2010;5(5):836-43.
- 618 56. Lew Q-LJ, Jafar TH, Koh HWL, Jin A, Chow KY, Yuan J-M, et al. Red meat  
619 intake and risk of ESRD. *Journal of the American Society of Nephrology: JASN*.  
620 2017;28(1):304.
- 621 57. van Nielen M, Edith Feskens JM, Rietman A, Siebelink E, Mensink M.  
622 Partly Replacing Meat Protein with Soy Protein Alters Insulin Resistance and  
623 Blood Lipids in Postmenopausal Women with Abdominal Obesity. *The Journal*  
624 *of Nutrition*. 2014;144(9):1423-9.
- 625 58. Kawamoto R, Akase T, Ninomiya D, Kumagi T, Kikuchi A. Metabolic  
626 syndrome is a predictor of decreased renal function among community-  
627 dwelling middle-aged and elderly Japanese. *International Urology and*  
628 *Nephrology*. 2019;51:2285-94.
- 629 59. Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan  
630 SD. Metabolic syndrome and kidney disease: a systematic review and meta-  
631 analysis. *Clinical journal of the American Society of Nephrology: CJASN*.  
632 2011;6(10):2364.
- 633 60. Qin P, Li Q, Zhao Y, Chen Q, Sun X, Liu Y, et al. Sugar and artificially  
634 sweetened beverages and risk of obesity, type 2 diabetes mellitus,  
635 hypertension, and all-cause mortality: a dose-response meta-analysis of  
636 prospective cohort studies. *European Journal of Epidemiology*. 2020;35(7):655-  
637 71.
- 638 61. Lin J, Curhan GC. Associations of sugar and artificially sweetened soda  
639 with albuminuria and kidney function decline in women. *Clinical journal of the*  
640 *American Society of Nephrology: CJASN*. 2011;6(1):160.
- 641 62. Saldana TM, Basso O, Darden R, Sandler DP. Carbonated beverages and  
642 chronic kidney disease. *Epidemiology (Cambridge, Mass)*. 2007;18(4):501.
- 643 63. Shoham DA, Durazo-Arvizu R, Kramer H, Luke A, Vupputuri S, Kshirsagar  
644 A, et al. Sugary soda consumption and albuminuria: results from the National

- 645 Health and Nutrition Examination Survey, 1999–2004. *PloS one*.  
646 2008;3(10):e3431.
- 647 64. Malik VS, Pan A, Willett WC, Hu FB. Sugar-sweetened beverages and  
648 weight gain in children and adults: a systematic review and meta-analysis. *The*  
649 *American journal of clinical nutrition*. 2013;98(4):1084-102.
- 650 65. Te Morenga L, Mallard S, Mann J. Dietary sugars and body weight:  
651 systematic review and meta-analyses of randomised controlled trials and  
652 cohort studies. *BMJ (Clin Res Ed)* 346: e7492. 2012.
- 653 66. Kang D-H, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, et al. A  
654 role for uric acid in the progression of renal disease. *Journal of the American*  
655 *Society of Nephrology*. 2002;13(12):2888-97.
- 656 67. Zheng Z, Harman JL, Coresh J, Köttgen A, McAdams-DeMarco MA, Correa  
657 A, et al. The dietary fructose: vitamin C intake ratio is associated with  
658 hyperuricemia in african-american adults. *The Journal of Nutrition*.  
659 2018;148(3):419-26.
- 660 68. Taylor E, Curhan G. Fructose consumption and the risk of kidney stones.  
661 *Kidney international*. 2008;73(2):207-12.
- 662 69. Carter JL, Lewington S, Piernas C, Bradbury K, Key TJ, Jebb SA, et al.  
663 Reproducibility of dietary intakes of macronutrients, specific food groups, and  
664 dietary patterns in 211 050 adults in the UK Biobank study. *J Nutr Sci*.  
665 2019;8:e34-e.
- 666 70. Thompson AS, Tresserra-Rimbau A, Karavasiloglou N, Jennings A,  
667 Cantwell M, Hill C, et al. Association of Healthful Plant-based Diet Adherence  
668 With Risk of Mortality and Major Chronic Diseases Among Adults in the UK.  
669 *JAMA Network Open*. 2023;6(3):e234714-e.
- 670 71. Eknoyan G, Lameire N, Eckardt K, Kasiske B, Wheeler D, Levin A, et al.  
671 KDIGO 2012 clinical practice guideline for the evaluation and management of  
672 chronic kidney disease. *Kidney int*. 2013;3(1):5-14.
- 673 72. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al.  
674 Comparison of sociodemographic and health-related characteristics of UK  
675 Biobank participants with those of the general population. *Am J Epidemiol*.  
676 2017;186(9):1026-34.
- 677 73. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US  
678 commentary on the 2012 KDIGO clinical practice guideline for the evaluation  
679 and management of CKD. *Am J Kidney Dis*. 2014;63(5):713-35.

680

681

682

683

**Table 1.** Baseline characteristics across quartiles (Q) of the healthful plant-based diet index in the UK Biobank (n=4,807)

Characteristics across hPDI	Participants, No. (%) <sup>a</sup>				
	Q1	Q2	Q3	Q4	Whole sample
<b>Number of participants</b>	1,309 (27.2)	1,239 (25.8)	1,131 (25.5)	1,128 (23.5)	4,807 (100.0)
<b>Mortality cases</b>	236 (18.0)	168 (13.6)	140 (12.4)	131 (11.6)	675 (14.0)
<b>Healthful plant-based diet index, mean (SD)</b>	49.7 (3.2)	55.6 (1.5)	59.5 (1.5)	64.9 (2.7)	57.1 (6.0)
<b>Sex-Female</b>	631 (48.2)	631 (50.9)	598 (52.9)	592 (52.5)	2,452 (51.0)
<b>Age at recruitment (years), mean (SD)</b>	60.1 (7.3)	61.1 (6.9)	61.5 (6.6)	61.3 (6.5)	60.9 (6.5)
<b>BMI (kg/m<sup>2</sup>), mean (SD)</b>	29.5 (5.8)	28.5 (4.9)	28.2 (5.0)	27.7 (4.7)	28.5 (5.2)
<b>Waist circumference (cm), mean (SD)</b>	96.9 (14.9)	93.9 (14.0)	93.1 (13.5)	91.9 (13.3)	94.0 (14.1)
<b>Energy intake (kJ/day), mean (SD)</b>	9125.7 (2298.2)	8370.9 (2107.8)	7997.0 (2139.7)	7810.8 (2118.5)	8357.1 (2229.9)
<b>Physical activity (MET-h/wk), mean (SD)</b>	28.6 (45.8)	28.2 (38.3)	29.4 (36.0)	33.8 (43.2)	29.9 (41.2)
<b>Ethnicity</b>					
Asian	47 (3.6)	46 (3.7)	43 (3.8)	37 (3.3)	173 (3.6)
Black	1 (0.1)	3 (0.2)	7 (0.6)	2 (0.2)	13 (0.3)
Multiple	41 (3.1)	46 (3.7)	32 (2.8)	39 (3.5)	158 (3.3)
White	1,205 (92.1)	1,130 (91.2)	1,034 (91.4)	1,033 (91.6)	4,402 (91.6)
Other/missing <sup>b</sup>	15 (1.2)	14 (1.1)	15 (1.3)	17 (1.5)	61 (1.3)
<b>Education<sup>c</sup></b>					
Low	332 (25.4)	282 (22.8)	280 (24.8)	257 (22.8)	1,152 (24.0)
Medium	211 (16.1)	200 (16.1)	177 (15.7)	199 (17.6)	787 (16.4)
High	522 (40.0)	548 (44.2)	515 (45.5)	531 (47.1)	2,116 (44.0)
Missing	244 (18.6)	208 (16.8)	159 (14.1)	141 (12.5)	752 (15.6)
<b>Smoking status</b>					
Never	670 (51.2)	666 (53.8)	571 (50.5)	597 (52.9)	2,504 (52.1)
Previous	527 (40.3)	497 (40.1)	500 (44.2)	466 (41.3)	1,990 (41.4)
Current	110 (8.4)	71 (5.7)	56 (5.0)	62 (5.5)	299 (6.2)
Missing	2 (0.2)	5 (0.4)	4 (0.6)	3 (0.3)	14 (0.3)
<b>Alcohol intake (g/day), mean (SD)</b>	13.4 (19.6)	13.5 (18.5)	13.6 (19.4)	12.3 (19.6)	13.2 (19.3)
<b>Prevalent diabetes</b>	168 (12.8)	136 (11.0)	112 (9.9)	127 (11.3)	543 (11.3)
<b>Multimorbidity</b>					
0 LTCs	361 (27.6)	343 (27.7)	333 (29.4)	334 (29.6)	1,371 (28.5)
1 LTC	315 (24.1)	317 (25.6)	317 (28.0)	293 (26.0)	1,242 (25.8)
2 LTCs	302 (23.1)	296 (23.9)	247 (21.8)	275 (24.4)	1,120 (23.3)
≥3 LTCs	331 (25.3)	283 (22.8)	234 (20.7)	226 (20.0)	1,074 (22.3)
<b>eGFR (mL/min/1.73 m<sup>2</sup>), mean (SD)</b>	58.9 (18.6)	59.2 (18.0)	58.7 (16.6)	61.3 (18.4)	59.5 (18.0)
<b>Protein intake (g/day), mean (SD)</b>	83.9 (25.0)	79.6 (22.6)	77.7 (23.6)	76.9 (22.4)	79.7 (23.6)
<b>hPDI food item intake (portion/day)<sup>d</sup>, mean (SD)</b>					
<b>Healthy plant food</b>					
Whole grains	1.4 (1.4)	1.9 (1.6)	2.2 (1.6)	2.7 (1.7)	2.0 (1.6)
Fruit	1.5 (1.3)	1.9 (1.5)	2.3 (1.7)	3.1 (1.9)	2.2 (1.7)
Vegetables	1.6 (1.6)	2.0 (1.9)	2.5 (2.2)	3.4 (2.5)	2.4 (2.2)
Nuts	0.1 (0.2)	0.1 (0.3)	0.1 (0.3)	0.2 (0.5)	0.1 (0.4)
Legumes	0.2 (0.4)	0.3 (0.5)	0.4 (0.5)	0.6 (0.7)	0.4 (0.5)
Tea and coffee	3.8 (1.8)	4.1 (1.7)	4.5 (1.8)	4.8 (1.8)	4.3 (1.8)
<b>Unhealthy plant food</b>					
Refined grains	1.9 (1.5)	1.2 (1.2)	0.9 (1.1)	0.6 (0.9)	1.2 (1.3)
Potatoes	0.9 (0.7)	0.8 (0.7)	0.7 (0.6)	0.6 (0.6)	0.7 (0.6)
Sugar-sweetened beverages	1.0 (1.2)	0.6 (0.9)	0.4 (0.8)	0.3 (0.7)	0.6 (1.0)
Fruit juices	0.5 (0.6)	0.5 (0.6)	0.4 (0.6)	0.3 (0.6)	0.4 (0.6)
Sweets and desserts	2.0 (1.6)	1.6 (1.3)	1.3 (1.3)	0.9 (1.1)	1.5 (1.4)
<b>Animal-derived food</b>					

Animal fat	1.3 (1.4)	0.8 (1.2)	0.5 (1.0)	0.3 (0.7)	0.8 (1.2)
Dairy	1.2 (0.9)	1.1 (0.8)	1.0 (0.8)	0.9 (0.8)	1.0 (0.9)
Eggs	0.4 (0.6)	0.3 (0.5)	0.2 (0.5)	0.2 (0.4)	0.3 (0.5)
Fish or seafood	0.4 (0.5)	0.3 (0.5)	0.3 (0.5)	0.2 (0.4)	0.3 (0.5)
Meat	1.5 (1.1)	1.3 (1.0)	1.1 (0.9)	1.0 (0.8)	1.2 (1.0)
Miscellaneous animal-based foods	0.1 (0.4)	0.1 (0.2)	0.1 (0.3)	0.0 (0.2)	0.1 (0.3)

<sup>a</sup>Relative frequencies (%) include missing values which may not equate to 100%.

<sup>b</sup>Other includes any race or ethnic group not otherwise specified.

<sup>c</sup>Education was categorised as Low: CSEs or equivalent, O levels/GCSEs or equivalent; Medium: A levels/AS levels or equivalent, NVQ or HND or HNC or equivalent; High: College or University degree, other professional qualifications eg: nursing, teaching.

<sup>d</sup>Portion sizes were specified as a “serving” in the Oxford WebQ tool.

Abbreviations: *Q*, quartile; *hPDI*, healthful plant-based diet index; *BMI*, body mass index; *MET*, metabolic equivalent task; *SD*, standard deviation; *LTC*, long term condition; *eGFR*, estimated glomerular filtration rate.

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

**Table 2.** Hazard ratios (95% confidence intervals) of mortality among all individuals with chronic kidney disease across sex-specific quartiles (Q) of the healthful plant-based diet index (hPDI) and unhealthy plant-based diet index (uPDI) (n=4,807)

<b>hPDI</b>	Q1	Q2	Q3	Q4	P-trend
Cases/total	236/1,309	168/1,239	140/1,131	131/1,128	
HR (95% CI)					
Model 1	1.00 <sup>a</sup>	0.71 (0.58-0.87)	0.64 (0.52-0.79)	0.61 (0.49-0.75)	<0.001
Model 2	1.00 <sup>a</sup>	0.78 (0.64-0.96)	0.73 (0.58-0.91)	0.67 (0.53-0.84)	<0.001
<b>uPDI</b>	Q1	Q2	Q3	Q4	P-trend
Cases/total	151/1,250	177/1,374	157/1,148	190/1,035	
HR (95% CI)					
Model 1	1.00 <sup>a</sup>	1.11 (0.89-1.38)	1.20 (0.96-1.50)	1.66 (1.34-2.07)	<0.001
Model 2	1.00 <sup>a</sup>	1.07 (0.86-1.34)	1.22 (0.96-1.54)	1.49 (1.18-1.89)	0.004

Model 1 adjusted for sex and education; stratified by age (5-year categories) and region.

Model 2: Model 1 plus BMI, waist circumference, ethnicity, physical activity, smoking status, alcohol intake, energy intake, multimorbidity index, polypharmacy, Townsend deprivation index, prevalent diabetes, total protein intake and number of completed dietary assessments.

P-trend is for linear trend.

<sup>a</sup>Reference categories.

Abbreviations: Q, quartile; hPDI, healthful plant-based diet index; uPDI, unhealthy plant-based diet index; BMI, Body Mass Index; HR, hazard ratio; CI, confidence interval.

701

702

703

704

705

706

707

708

709

710

**Table 3.** Hazard ratios (95% confidence intervals) of mortality across key food groups from the plant-based diet index (n=4,807)

	Food group intake quartiles				P-trend
	Q1	Q2	Q3	Q4	
<b>Healthy Plant Foods</b>					
<b>Wholegrains</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	1.0 (0.1-1.4)	2.0 (1.5-2.9)	3.8 (2.9-11.0)	
Cases/total	130/685	189/1,375	178/1,369	178/1,378	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.76 (0.60-0.96)	0.82 (0.65-1.05)	0.71 (0.56-0.90)	0.02
<b>Fruit</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	1.0 (0.1-1.4)	2.0 (1.5-2.9)	3.8 (2.9-18.0)	
Cases/total	105/582	164/1,161	213/1,610	193/1,454	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.88 (0.68-1.14)	0.87 (0.68-1.12)	0.86 (0.66-1.11)	0.49
<b>Vegetables</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	1.0 (0.1-1.6)	2.3 (1.6-3.1)	4.5 (3.1-24.0)	
Cases/total	108/667	203/1,385	192/1,429	172/1,326	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.08 (0.84-1.38)	1.06 (0.82-1.36)	1.05 (0.81-1.37)	0.44
<b>Nuts</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.3)	0.5 (0.4-0.7)	1.0 (0.8-4.0)	
Cases/total	577/3,888	39/350	27/293	32/276	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.96 (0.68-1.35)	0.69 (0.46-1.02)	0.95 (0.66-1.37)	0.44
<b>Legumes</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.4-0.8)	1.0 (0.8-6.0)	
Cases/total	326/2,227	102/795	103/855	144/930	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.96 (0.75-1.24)	0.91 (0.71-1.15)	0.99 (0.81-1.21)	0.57
<b>Tea and coffee</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	3.0 (0.3-3.8)	4.5 (3.8-5.1)	6.0 (5.1-18.0)	
Cases/total	13/108	245/1,573	230/1,745	187/1,381	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.16 (0.65-2.05)	0.98 (0.55-1.75)	0.97 (0.54-1.74)	0.05
<b>Unhealthy Plant Foods</b>					
<b>Refined grains</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.9)	2.8 (2.0-9.0)	
Cases/total	172/1,257	119/1,032	166/1,298	218/1,220	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.08 (0.83-1.40)	0.97 (0.77-1.21)	1.28 (1.04-1.59)	0.002
<b>Potatoes</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.5 (0.1-0.1)	1.0 (0.6-1.0)	1.5 (1.1-5.0)	
Cases/total	137/1,033	141/1,117	267/1,827	130/830	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.12 (0.87-1.44)	1.13 (0.91-1.41)	1.21 (0.93-1.57)	0.38
<b>Sugar-sweetened beverages</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.4 (0.1-0.6)	1.0 (0.6-1.0)	2.0 (1.1-7.0)	
Cases/total	318/2,524	97/759	118/758	142/766	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.09 (0.86-1.39)	1.20 (0.97-1.50)	1.31 (1.06-1.62)	0.001
<b>Fruit juices</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.9)	1.0 (1.0-13.0)	

Cases/total	339/2,378	58/426	128/943	150/1,060	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.12 (0.83-1.52)	1.09 (0.88-1.34)	1.02 (0.84-1.25)	0.55
<b>Sweets and desserts</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.8 (0.1-1.1)	1.7 (1.1-2.1)	3.0 (2.1-9.0)	
Cases/total	131/930	177/1,525	172/1,177	195/1,175	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.88 (0.70-1.12)	1.08 (0.84-1.38)	1.10 (0.85-1.43)	0.22
<b>Animal-Derived Foods</b>					
<b>Animal fat</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.8 (0.1-1.0)	2.0 (1.1-2.0)	3.0 (2.1-11.0)	
Cases/total	368/2,818	107/780	105/694	95/515	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.21 (0.97-1.52)	1.04 (0.83-1.30)	1.16 (0.92-1.48)	0.14
<b>Dairy</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.4)	2.0 (1.5-7.0)	
Cases/total	133/834	150/1,246	195/1,301	197/1,426	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.88 (0.68-1.14)	1.04 (0.83-1.32)	0.91 (0.72-1.16)	0.61
<b>Eggs</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.9)	1.0 (1.0-5.0)	
Cases/total	418/3,037	44/445	90/564	123/761	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	0.89 (0.63-1.25)	1.24 (0.96-1.59)	0.98 (0.80-1.22)	0.39
<b>Fish and seafood</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.4-0.8)	1.0 (0.8-6.0)	
Cases/total	414/2,734	69/540	87/766	105/767	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.11 (0.82-1.49)	0.91 (0.71-1.17)	1.03 (0.82-1.29)	0.94
<b>Meat</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.5 (0.1-0.9)	1.0 (1.0-1.4)	2.0 (1.5-10.0)	
Cases/total	102/723	121/891	212/1,569	240/1,624	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.31 (0.98-1.75)	1.17 (0.90-1.50)	1.23 (0.94-1.61)	0.14
<b>Miscellaneous animal-based foods</b>					
Intake (servings/d) <sup>a</sup>	0 (0-0)	0.3 (0.1-0.4)	0.5 (0.5-0.8)	1.0 (1.0-4.0)	
Cases/total	621/4,428	14/110	18/109	22/160	
HR (95% CI) <sup>b</sup>	1.00 <sup>c</sup>	1.16 (0.67-2.02)	1.45 (0.90-2.35)	0.96 (0.62-1.49)	0.63

<sup>a</sup>Intake values are median (range) and portion sizes were specified as a “serving” in the Oxford WebQ tool.

<sup>b</sup>Hazard Ratios with 95% Confidence Intervals (CI) adjusted for sex, BMI, waist circumference, ethnicity, physical activity, smoking status, education, alcohol intake, energy intake, multimorbidity index, polypharmacy, Townsend deprivation index, prevalent diabetes, total protein intake and number of completed dietary assessments; stratified by age (5-year categories) and region.

<sup>c</sup>Reference categories.

P-trend is for linear trend.

Abbreviations: Q, quartile; BMI, Body Mass Index; HR, hazard ratio; CI, confidence interval.